BioRestorative Therapies, Inc. ("BRT" or the "Company")
(OTCBB:BRTX), a life sciences company focused on adult stem
cell-based therapies for various personal medical applications, today
announced that its ThermoStem® program has led to a study to be
published in the peer-reviewed journal Stem Cells. The newly
identified human adult brown fat stem cells discussed in the study have
the potential to lead to the development of a cell-based method for the
treatment of type 2 diabetes and obesity.
The study incorporates the Company’s preclinical research demonstrating
that functional brown adipocytes, differentiated from human adult brown
adipose (fat)-derived stem cells (BADSCs), produce improvements in mice
with diet-induced metabolic disorder. These studies provide
proof-of-concept for the therapeutic potential of these newly identified
BADSCs in the treatment of metabolic disorders such as diabetes. The
published study is available online here.
The results of this study show for the first time that a multipotent
stem cell population exists in human adult brown adipose depots and that
this population can be differentiated into metabolically functional
brown adipocytes. Brown adipocytes are key cells that are involved in
energy homeostasis and metabolism. In humans, loss of brown adipose
(fat) activity may account for the lower metabolism often associated
with diabetes and obesity.
Mark Weinreb, CEO of BRT, commented, “We are very excited to have our
work published in Stem Cells. This peer-reviewed publication of
our research is an important milestone for our company, and serves to
validate the work we are doing and the potential use of brown adipocytes
to treat and control the metabolic diseases that are straining our
healthcare system. We look forward to continuing to advance this
approach to treating diabetes and obesity with additional research,”
Weinreb added.
This study was conducted in collaboration with a team of researchers at
the University of Utah School of Medicine.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. (www.biorestorative.com)
develops products and medical procedures using cell and tissue
protocols, primarily involving adult stem cells, including:
-
brtxDISC™ (Disc Implanted Stem Cells)
is an investigational non-surgical treatment for bulging and herniated
lumbar discs that is intended for patients who have failed
non-invasive procedures and face the prospect of surgery. The
treatment involves culturing a patient’s own stem cells and then
delivering them via a proprietary medical device to the damaged region
of the disc in an outpatient procedure.
-
ThermoStem® is a treatment using brown fat stem cells that is
under development for metabolic disorders including diabetes and
obesity. Initial preclinical research indicates that increased amounts
of brown fat in the body may be responsible for additional caloric
burning as well as reduced glucose and lipid levels.
-
brtx-C Cosmetic is based on the development of a human cellular
extract that has been demonstrated in in vitro skin studies to
increase the production of collagen and fibronectin, which are
proteins that are essential to combating the aging of skin. Potential
cosmetic uses are being explored with third parties.
The Company also offers plant stem cell-based facial creams and beauty
products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the Company undertakes no obligation to
update such statements.
Copyright Business Wire 2013